Sarepta Therapeutics annual cash and equivalents
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Cash & Equivalents Growth & History (SRPT)
Sarepta Therapeutics's cash and equivalents was $801.3M for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $801.3M | −$301.7M | −27.35% |
| 2024 | 2024-12-31 | $1.10B | $674.6M | +157.45% |
| 2023 | 2023-12-31 | $428.4M | −$538.3M | −55.68% |
| 2022 | 2022-12-31 | $966.8M | −$1.15B | −54.31% |
| 2021 | 2021-12-31 | $2.12B | $613.2M | +40.81% |
| 2020 | 2020-12-31 | $1.50B | $667.6M | +79.94% |
| 2019 | 2019-12-31 | $835.1M | $464.3M | +125.19% |
| 2018 | 2018-12-31 | $370.8M | −$228.9M | −38.16% |
| 2017 | 2017-12-31 | $599.7M | $477.3M | +389.86% |
| 2016 | 2016-12-31 | $122.4M | $42.1M | +52.45% |
| 2015 | 2015-12-31 | $80.3M | $6.8M | +9.18% |
| 2014 | 2014-12-31 | $73.6M | −$183.4M | −71.38% |
| 2013 | 2013-12-31 | $257.0M | $69.3M | +36.93% |
| 2012 | 2012-12-31 | $187.7M | $147.8M | +370.28% |
| 2011 | 2011-12-31 | $39.9M | $6.3M | +18.80% |
| 2010 | 2010-12-31 | $33.6M | −$14.7M | −30.42% |
| 2009 | 2009-12-31 | $48.3M | — | — |
Sarepta Therapeutics quarterly cash and equivalents
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $571.1M | $60.5M | +11.86% |
| Q1 2026 | 2026-03-31 | $464.4M | $223.6M | +92.82% |
| Q4 2025 | 2025-12-31 | $801.3M | −$301.7M | −27.35% |
| Q3 2025 | 2025-09-30 | $613.1M | $415.2M | +209.86% |
| Q2 2025 | 2025-06-30 | $510.6M | $127.0M | +33.10% |
| Q1 2025 | 2025-03-31 | $240.9M | −$186.4M | −43.63% |
| Q4 2024 | 2024-12-31 | $1.10B | $674.6M | +157.45% |
| Q3 2024 | 2024-09-30 | $197.9M | −$344.1M | −63.49% |
| Q2 2024 | 2024-06-30 | $383.6M | −$468.3M | −54.97% |
| Q1 2024 | 2024-03-31 | $427.3M | −$444.4M | −50.98% |
| Q4 2023 | 2023-12-31 | $428.4M | −$538.3M | −55.68% |
| Q3 2023 | 2023-09-30 | $541.9M | −$496.7M | −47.82% |
| Q2 2023 | 2023-06-30 | $851.9M | −$16.6M | −1.92% |
| Q1 2023 | 2023-03-31 | $871.7M | −$362.2M | −29.36% |
| Q4 2022 | 2022-12-31 | $966.8M | −$1.15B | −54.31% |
| Q3 2022 | 2022-09-30 | $1.04B | −$560.5M | −35.05% |
| Q2 2022 | 2022-06-30 | $868.6M | −$828.7M | −48.83% |
| Q1 2022 | 2022-03-31 | $1.23B | −$248.0M | −16.73% |
| Q4 2021 | 2021-12-31 | $2.12B | $613.2M | +40.81% |
| Q3 2021 | 2021-09-30 | $1.60B | $124.5M | +8.44% |
| Q2 2021 | 2021-06-30 | $1.70B | $57.3M | +3.49% |
| Q1 2021 | 2021-03-31 | $1.48B | −$282.4M | −16.01% |
| Q4 2020 | 2020-12-31 | $1.50B | $667.6M | +79.94% |
| Q3 2020 | 2020-09-30 | $1.47B | $749.8M | +103.45% |
| Q2 2020 | 2020-06-30 | $1.64B | $831.4M | +102.82% |
| Q1 2020 | 2020-03-31 | $1.76B | $1.03B | +140.95% |
| Q4 2019 | 2019-12-31 | $835.1M | $464.3M | +125.19% |
| Q3 2019 | 2019-09-30 | $724.8M | $515.1M | +245.65% |
| Q2 2019 | 2019-06-30 | $808.6M | $398.2M | +97.04% |
| Q1 2019 | 2019-03-31 | $732.2M | $175.0M | +31.40% |
| Q4 2018 | 2018-12-31 | $370.8M | −$228.9M | −38.16% |
| Q3 2018 | 2018-09-30 | $209.7M | −$407.9M | −66.05% |
| Q2 2018 | 2018-06-30 | $410.4M | $242.0M | +143.77% |
| Q1 2018 | 2018-03-31 | $557.2M | $282.5M | +102.83% |
| Q4 2017 | 2017-12-31 | $599.7M | $477.3M | +389.86% |
| Q3 2017 | 2017-09-30 | $617.6M | $222.5M | +56.31% |
| Q2 2017 | 2017-06-30 | $168.3M | $56.5M | +50.55% |
| Q1 2017 | 2017-03-31 | $274.7M | $236.7M | +622.94% |
| Q4 2016 | 2016-12-31 | $122.4M | $42.1M | +52.45% |
| Q3 2016 | 2016-09-30 | $395.1M | $339.3M | +607.90% |
| Q2 2016 | 2016-06-30 | $111.8M | $42.3M | +60.80% |
| Q1 2016 | 2016-03-31 | $38.0M | −$36.4M | −48.95% |
| Q4 2015 | 2015-12-31 | $80.3M | $6.8M | +9.18% |
| Q3 2015 | 2015-09-30 | $55.8M | $3.5M | +6.73% |
| Q2 2015 | 2015-06-30 | $69.5M | −$33.2M | −32.33% |
| Q1 2015 | 2015-03-31 | $74.4M | $25.3M | +51.60% |
| Q4 2014 | 2014-12-31 | $73.6M | −$183.4M | −71.38% |
| Q3 2014 | 2014-09-30 | $52.3M | −$221.3M | −80.89% |
| Q2 2014 | 2014-06-30 | $102.8M | −$53.4M | −34.21% |
| Q1 2014 | 2014-03-31 | $49.1M | −$118.8M | −70.76% |
| Q4 2013 | 2013-12-31 | $257.0M | $69.3M | +36.93% |
| Q3 2013 | 2013-09-30 | $273.6M | $235.7M | +620.36% |
| Q2 2013 | 2013-06-30 | $156.2M | $131.7M | +537.72% |
| Q1 2013 | 2013-03-31 | $167.9M | $137.3M | +449.24% |
| Q4 2012 | 2012-12-31 | $187.7M | $147.8M | +370.28% |
| Q3 2012 | 2012-09-30 | $38.0M | −$8.4M | −18.05% |
| Q2 2012 | 2012-06-30 | $24.5M | −$29.7M | −54.80% |
| Q1 2012 | 2012-03-31 | $30.6M | — | — |
| Q4 2011 | 2011-12-31 | $39.9M | $6.3M | +18.80% |
| Q3 2011 | 2011-09-30 | $46.4M | — | — |
| Q2 2011 | 2011-06-30 | $54.2M | — | — |
| Q4 2010 | 2010-12-31 | $33.6M | — | — |
Sarepta Therapeutics cash and equivalents trends
Over the last five fiscal years, Sarepta Therapeutics's cash and equivalents decreased from $1.50B to $801.3M, a change of −$701.4M. The latest reported quarter, Q2 2026, shows $571.1M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...